biostudies-literatureUnknown15(1)Abbott L<h4>Background</h4>Prior to the introduction of disease-modifying treatments (DMTs), children with type 1 spinal muscular atrophy (SMA) typically did not survive beyond the age of 2 years; management was mainly palliative. Novel therapies have made this a treatable condition, resulting in increased life expectancy and more time spent upright. Survival and improved function mean spinal asymmetry is a new complication with limited data on its prevalence and severity and no current guidelines on management and treatment. This study aimed to evaluate the spinal presentation and management of type 1 SMA children on nusinersen across the SMA-REACH UK network.<h4>Methods</h4>Spinal presentation and management of 80 children (age range 4 months-14 years, median 4 years 2 months) with type 1 SMA onBMJ opene082240https://www.ebi.ac.uk/biostudies/studies/S-EPMC11784377biostudies-literatureSpinal presentations in children with type 1 spinal muscular atrophy on nusinersen treatment across the SMA-REACH UK network: a retrospective national observational study.PMC11784377Scoto MWhite KEmery ND'Urso SMilev EPallant LMason FSheehan JMcMurchie HLongatto JRohwer AMunot PRaab RNicFhirleinn GSMA-REACH UK Network PhysiotherapistsGregson SSelby VWolfe ATopping AManzur APanagiotopoulou EAbbott LMain MMuntoni FBaranello GWadsworth SMoustoukas JVann FRye CfalseSpinal presentations in children with type 1 spinal muscular atrophy on nusinersen treatment across the SMA-REACH UK network: a retrospective national observational study.<h4>Background</h4>Prior to the introduction of disease-modifying treatments (DMTs), children with type 1 spinal muscular atrophy (SMA) typically did not survive beyond the age of 2 years; management was mainly palliative. Novel therapies have made this a treatable condition, resulting in increased life expectancy and more time spent upright. Survival and improved function mean spinal asymmetry is a new complication with limited data on its prevalence and severity and no current guidelines on management and treatment. This study aimed to evaluate the spinal presentation and management of type 1 SMA children on nusinersen across the SMA-REACH UK network.<h4>Methods</h4>Spinal presentation and management of 80 children (age range 4 months-14 years, median 4 years 2 months) with type 1 SMA on2025-01-01T00:00:00Z2025 Jan2026-06-06T23:42:05.76Z2026-06-06T03:11:10.047ZS-EPMC117843773984291010.1136/bmjopen-2023-082240